Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticancer Therapeutic Strategies Targeting p53 Aggregation.

International journal of molecular sciences - 20 Sept 2022

Ferretti Giulia D S, Quarti Julia, Dos Santos Gileno, Rangel Luciana P, Silva Jerson L

Abstract excerpt

p53 is a tumor suppressor protein that is mutated in more than 50% of cancer cases. When mutated, it frequently results in p53 oncogenic gain of function (GOF), resulting in a greater tendency to aggregate in the phase separation and phase transition pathway. GOFs related to p53 aggregation include chemoresistance, which makes therapy even more difficult. The therapies available for the treatment of cancer are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkylating Agents
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Peptides

Share to Sulfhydryl Compounds

Share to Tumor Suppressor Protein p53

Share to Tumor Suppressor Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 36232329
DOI: 10.3390/ijms231911023
PMCID: PMC9569952

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticancer Therapeutic Strategies Targeting p53 Aggregation.PMID 36232329Read ↗

Inhibition of p53 protein aggregation as a cancer treatment strategy.Semantic proximity Read ↗

Treating p53 Mutant Aggregation-Associated CancerSemantic proximity Read ↗

Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.Semantic proximity Read ↗

Amyloidogenicity of p53: A Hidden Link Between Protein Misfolding and CancerSemantic proximity Read ↗

p53 amyloid aggregation in cancer: function, mechanism, and therapySemantic proximity Read ↗

Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.Semantic proximity Read ↗

Anticancer therapeutic strategies for targeting mutant p53-Y220CSemantic proximity Read ↗

Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor functionSemantic proximity Read ↗

Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.Semantic proximity Read ↗

Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers.Semantic proximity Read ↗

Phase Separation and Prion‐Like Aggregation of p53 Family Tumor Suppressors: From Protein Evolution to Cancer TreatmentSemantic proximity Read ↗

The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy - Drug RepurposingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.